173 related articles for article (PubMed ID: 36439183)
21. Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway.
Hua H; Zhu Y; Song YH
Biomed Pharmacother; 2018 May; 101():115-122. PubMed ID: 29477471
[TBL] [Abstract][Full Text] [Related]
22. Long noncoding RNA HAGLROS promotes cell proliferation, inhibits apoptosis and enhances autophagy via regulating miR-5095/ATG12 axis in hepatocellular carcinoma cells.
Wei H; Hu J; Pu J; Tang Q; Li W; Ma R; Xu Z; Tan C; Yao T; Wu X; Long X; Wang J
Int Immunopharmacol; 2019 Aug; 73():72-80. PubMed ID: 31082725
[TBL] [Abstract][Full Text] [Related]
23. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
[No Abstract] [Full Text] [Related]
24. PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma.
Wang Z; Rehman AU; Qin X; Zhu C; Wu S
Dis Markers; 2022; 2022():7545666. PubMed ID: 35592706
[TBL] [Abstract][Full Text] [Related]
25. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
26. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway.
Chen J; Chen J; Huang J; Li Z; Gong Y; Zou B; Liu X; Ding L; Li P; Zhu Z; Zhang B; Guo H; Cai C; Li J
Aging (Albany NY); 2019 Dec; 11(23):10839-10860. PubMed ID: 31796646
[TBL] [Abstract][Full Text] [Related]
27. Comparative RNA-Sequencing Analysis Reveals High Complexity and Heterogeneity of Transcriptomic and Immune Profiles in Hepatocellular Carcinoma Tumors of Viral (HBV, HCV) and Non-Viral Etiology.
Paslaru L; Bindea G; Nastase A; Sorop A; Zimbru C; Herlea V; Hrehoret D; Brasoveanu V; Zamfir R; Dima S; Popescu I
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557005
[TBL] [Abstract][Full Text] [Related]
28. LncRNA MAPKAPK5_AS1 facilitates cell proliferation in hepatitis B virus -related hepatocellular carcinoma.
Tao L; Li D; Mu S; Tian G; Yan G
Lab Invest; 2022 May; 102(5):494-504. PubMed ID: 35264707
[TBL] [Abstract][Full Text] [Related]
29. Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways.
Li Y; Xiong H
BMC Cancer; 2022 Mar; 22(1):298. PubMed ID: 35313850
[TBL] [Abstract][Full Text] [Related]
30. Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study.
Ramadan HK; Badr G; Ramadan NK; Sayed A
Pathog Dis; 2021 Mar; 79(3):. PubMed ID: 33524139
[TBL] [Abstract][Full Text] [Related]
31. MiR-92a-3p Promotes the Malignant Progression of Hepatocellular Carcinoma by Mediating the PI3K/AKT/mTOR Signaling Pathway.
Wang L; Cui M; Qu F; Cheng D; Yu J; Tang Z; Cheng L; Wei Y; Wu X; Liu X
Curr Pharm Des; 2021; 27(29):3244-3250. PubMed ID: 34126886
[TBL] [Abstract][Full Text] [Related]
32. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
Yen CS; Su ZR; Lee YP; Liu IT; Yen CJ
World J Gastroenterol; 2016 Jun; 22(22):5183-92. PubMed ID: 27298561
[TBL] [Abstract][Full Text] [Related]
33. Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma.
Zhou L; Zhao Y; Pan LC; Wang J; Shi XJ; Du GS; He Q
World J Gastroenterol; 2022 Aug; 28(32):4600-4619. PubMed ID: 36157928
[TBL] [Abstract][Full Text] [Related]
34. Study on the anti-tumor mechanism related to immune microenvironment of Bombyx Batryticatus on viral and non-viral infections of hepatocellular carcinoma.
Yuan L; Bing Z; Han J; An X; Liu X; Li R; Wang C; Sun X; Yang L; Yang K
Biomed Pharmacother; 2020 Apr; 124():109838. PubMed ID: 31981943
[TBL] [Abstract][Full Text] [Related]
35. Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K/Akt/mTOR signaling pathway.
Wang SS; Chen YH; Chen N; Wang LJ; Chen DX; Weng HL; Dooley S; Ding HG
Cell Death Dis; 2017 Mar; 8(3):e2688. PubMed ID: 28333142
[TBL] [Abstract][Full Text] [Related]
36. DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis.
Wu Y; Xu X; Liu M; Qin X; Wu Q; Ding H; Zhao Q
Biochem Pharmacol; 2022 Jul; 201():115093. PubMed ID: 35580648
[TBL] [Abstract][Full Text] [Related]
37. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
38. [Research advances in the mammalian target of rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma].
Li SZ; Xu F; Sun CQ; Xu P
Zhonghua Gan Zang Bing Za Zhi; 2018 Jan; 26(1):77-80. PubMed ID: 29804369
[TBL] [Abstract][Full Text] [Related]
39. FSTL1 Secreted by Activated Fibroblasts Promotes Hepatocellular Carcinoma Metastasis and Stemness.
Loh JJ; Li TW; Zhou L; Wong TL; Liu X; Ma VWS; Lo CM; Man K; Lee TK; Ning W; Tong M; Ma S
Cancer Res; 2021 Nov; 81(22):5692-5705. PubMed ID: 34551961
[TBL] [Abstract][Full Text] [Related]
40. LncRNA DCST1-AS1 accelerates the proliferation, metastasis and autophagy of hepatocellular carcinoma cell by AKT/mTOR signaling pathways.
Li J; Zhai DS; Huang Q; Chen HL; Zhang Z; Tan QF
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6091-6104. PubMed ID: 31364110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]